PDF(Pubmed)
Abstract：
Chemokine ligand 11 is a member of the CXC chemokine family and exerts its biological function mainly through binding to CXCR3 and CXCR7. The CXCL11 gene is ubiquitously overexpressed in various human malignant tumors; however, its specific mechanisms vary among different cancer types. Recent studies have found that CXCL11 is involved in the activation of multiple oncogenic signaling pathways and is closely related to tumorigenesis, progression, chemotherapy tolerance, immunotherapy efficacy, and poor prognosis. Depending on the specific expression of its receptor subtype, CXCL11 also has a complex 2-fold role in tumours; therefore, directly targeting the structure-function of CXCL11 and its receptors may be a challenging task. In this review, we summarize the biological functions of CXCL11 and its receptors and their roles in various types of malignant tumors and point out the directions for clinical applications.
CXCL11 is found in many types of cancer and affects how cancer cells grow and respond to treatments. This paper delves into the intricate dance between CXCL11 and its receptors in various types of cancer. Like a versatile actor playing different roles on stage, CXCL11 can either promote or hinder cancer growth depending on its interaction with specific receptors. Understanding how CXCL11 works could help develop new treatments for cancer, but it\'s a complex challenge because CXCL11 can have different effects depending on the type of cancer and which receptors it binds to.
CXCL11 is found in many types of cancer and affects how cancer cells grow and respond to treatments. This paper delves into the intricate dance between CXCL11 and its receptors in various types of cancer. Like a versatile actor playing different roles on stage, CXCL11 can either promote or hinder cancer growth depending on its interaction with specific receptors. Understanding how CXCL11 works could help develop new treatments for cancer, but it\'s a complex challenge because CXCL11 can have different effects depending on the type of cancer and which receptors it binds to.
摘要：
趋化因子配体11是CXC趋化因子家族的一员,主要通过与CXCR3和CXCR7结合发挥其生物学功能。CXCL11基因在各种人类恶性肿瘤中普遍过表达；然而，其具体机制因癌症类型而异。近年来研究发现,CXCL11参与多种致癌信号通路的激活,与肿瘤发生、programming,化疗耐受性，免疫治疗疗效，预后不良。根据其受体亚型的特异性表达，CXCL11在肿瘤中也具有复杂的2倍作用；因此，直接靶向CXCL11及其受体的结构功能可能是一项具有挑战性的任务。在这次审查中,本文对CXCL11及其受体的生物学功能及其在各类恶性肿瘤中的作用进行了综述，并指出了临床应用的方向。
CXCL11在许多类型的癌症中发现，并影响癌细胞的生长和对治疗的反应。本文探讨了CXCL11及其受体在各种类型癌症中的复杂舞蹈。就像一个多才多艺的演员在舞台上扮演不同的角色，CXCL11可以促进或阻碍癌症生长，这取决于其与特定受体的相互作用。了解CXCL11的工作原理可以帮助开发新的癌症治疗方法，但它是一个复杂的挑战，因为CXCL11可以有不同的影响取决于癌症的类型和受体结合。
CXCL11在许多类型的癌症中发现，并影响癌细胞的生长和对治疗的反应。本文探讨了CXCL11及其受体在各种类型癌症中的复杂舞蹈。就像一个多才多艺的演员在舞台上扮演不同的角色，CXCL11可以促进或阻碍癌症生长，这取决于其与特定受体的相互作用。了解CXCL11的工作原理可以帮助开发新的癌症治疗方法，但它是一个复杂的挑战，因为CXCL11可以有不同的影响取决于癌症的类型和受体结合。
